News and Events, Recent News

BriaCell’s Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal

BERKELEY, Calif. and VANCOUVER, British Columbia, April 3, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the acceptance of a manuscript describing the novel mechanism of action of the Company’s lead product candidate, Bria-IMT™. The findings detailed in […]

News and Events, Recent News

BriaCell Completes Previously Announced Oversubscribed Non-Brokered Private Placement and Concurrent Investment with Leading U.S. Biotech Funds

BERKELEY, Calif. and VANCOUVER, British Columbia, March 27, 2018 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that the Company has completed both its previously announced brokered and non-brokered private placement financings. BriaCell completed a non-brokered private placement […]

News and Events, Recent News

BriaCell Appoints Top Social Media Marketing Analyst

BERKELEY, Calif. and VANCOUVER, British Columbia, March 14, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it has engaged Akari Health, a leading health-care focused social media marketing company, to improve awareness of its lead product candidate, Bria-IMT™, as a […]

News and Events, Recent News

BriaCell Announces Proposed Investment by Leading Biotech Funds and Concurrent Non-Brokered Financing for aggregate gross proceeds of up to $4.8 Million

BERKELEY, Calif. and VANCOUVER, British Columbia, March 07, 2018 –BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it expects to enter into a securities purchase agreement of convertible notes with a leading group of Institutional and Family Office funds focused […]

News and Events, Recent News

BriaCell To Present at Precision Breast Cancer Conference

BERKELEY, Calif. and VANCOUVER, British Columbia, March 1, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that Dr. Bill Williams, BriaCell’s President & CEO, has been invited to present at Precision Breast Cancer Conference, a global Pharma R&D summit, in Boston, […]

News and Events, Recent News

BriaCell to Attend 20th Annual BIO CEO & Investor Conference

BERKELEY, Calif. and VANCOUVER, British Columbia, February 7, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it will be attending BIO CEO & Investor Conference 2018. The conference will be held February 12-13, 2018 at New York Marriott Marquis Hotel […]

News and Events, Recent News

BriaCell Opens Fourth Clinical Site in Advanced Breast Cancer

BERKELEY, Calif. and VANCOUVER, British Columbia, February 6, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the opening of a new clinical site, Jefferson Breast Care Center in Philadelphia, PA, and the appointment of Dr. Saveri Bhattacharya, a […]

News and Events, Recent News

BriaCell Presenting at Upcoming Cancer Conference

– Further Investigation on Mechanism of Action of its Lead Drug Candidate, Bria-IMT™, at AACR event – BERKELEY, Calif. and VANCOUVER, British Columbia, February 5, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, will present a poster on the mechanism of action […]

News and Events, Recent News

BriaCell Update: Early Evidence of Efficacy and Safety of Bria-IMT™

BERKELEY, Calif. and VANCOUVER, British Columbia, January 31, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, provides an update on its operations. Recent Corporate Milestones Recent Clinical Update: BriaCell is pleased to provide a further update on its ongoing clinical trial of […]

Recent News

BriaCell Provides Clinical Update on its Lead Immunotherapy Drug in Advanced Breast Cancer

BERKELEY, Calif. and VANCOUVER, British Columbia, January 3, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is providing a clinical update regarding its ongoing clinical trials of Bria-IMT™ (formerly referred to as SV-BR-1-GM). BriaCell currently is enrolling patients in two separate but […]